With total assets of 9.1 billion yuan and over 6,000 employees, Lukang Pharma is a leading enterprise primarily engaged in the production of human-use APIs, human-use FDFs, animal and plant health products, and environmental protection and technology which are exported to more than 60 countries and regions.
Lukang Pharma serves as a vice-chairman unit of the China Chemical Pharmaceutical Industry Association, China Pharmaceutical Enterprise Management Association, and Shandong Pharmaceutical Administration Association. Recognized as a leader in Shandong Province's "Top 10" industrial clusters, ranked 48th in the "2023 China Pharmaceutical Industry Top 100 List."
Lukang Pharma is a national high-tech enterprise and a pilot enterprise for the integration of industrialization and informatization under the Ministry of Industry and Information Technology (MIIT). It has been designated as a national "Green Factory" by MIIT and a key export brand under the Ministry of Commerce. The company has received numerous honors, including National Quality & Efficiency Advanced Enterprise, Pharmaceutical Quality Integrity Demonstration Enterprise, AAA Credit Enterprise, and China's Most Valuable Pharmaceutical Brand. In Shandong Province, it is recognized as a leader in the "Top 10" industrial clusters, a high-end brand cultivation enterprise, one of the first "Morning Star Factories," a provincial high-quality development award recipient, a quality benchmark enterprise, a provincial smart factory, and one of the first provincial-level digital economy innovation platforms. In Jining City, it serves as a leading enterprise in the biopharmaceutical industry and climbing projects.
Lukang Pharma currently operates six national high-tech enterprises, one national-level enterprise technology center, and two Shandong provincial-level enterprise technology centers. It is among the first batch of "National Comprehensive New Drug R&D Technology Platform (Shandong) Industrial Demonstration Enterprises" and a "National Torch Plan Key High-Tech Enterprise." Lukang Pharma has established multiple R&D platforms, including the Shandong Industrial Biotechnology Transformation Platform, Shandong Brand International Cooperation Center, Shandong University-Lukang Microbial Technology Research Institute, China-Cuba Biotechnology International Cooperation Center, an academician workstation, and a postdoctoral research station.
As one of China's top 100 pharmaceutical R&D enterprises, Lukang Pharma has undertaken key national projects such as the 863 Program, major national science and technology research initiatives, and the "14th Five-Year Plan" National Key R&D Program's "Synthetic Biology" project.
New era, new journey, new Lukang, new future. Lukang Pharma is committed to embracing new development phases, implementing innovative concepts, and building a new development framework to drive high-quality growth, aims to achieve breakthroughs in innovative drug R&D, biotechnology applications, intelligent manufacturing, and excellence in performance management, contributing to the advancement of China's pharmaceutical industry and global health.
